A pilot study to explore the tolerability and efficacy of bortezomib as part of induction and post-transplant therapy in multiple myeloma
Phase 2
Completed
- Conditions
- Multiple myelomaCancer - Myeloma
- Registration Number
- ACTRN12605000770662
- Lead Sponsor
- Clinical Haematology & Bone Marrow Transplant Unit, Royal Adelaide Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Previously untreated, advanced multiple myeloma, planned for autologous PBSCT, absence of significant co-morbidity.
Exclusion Criteria
No exclusion criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method